A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Status:
Recruiting
Trial end date:
2024-03-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum
tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin
lymphoma and chronic lymphocytic leukemia.